biOasis Technologies Ord Shs V.BTI.H

BiOasis Vs Annexon!

[narmac]

Just tried to do a comparison between the two yesterday. I really think ANNX is well ahead of BTI in progress as they are in the clinic from what I can gather with Pll data and more coming. I will assume when DrDR made the comparison she was pointing out where we could be in a years time or there about. If you brainy investors would have a lookie at the ANNX presentation on their web site and comment.

[narmac]

Sept.14th blurb,,,,! Annexon, Inc. (NASDAQ:ANNX – Get Rating) has been given an average recommendation of “Buy” by the six brokerages that are covering the company, MarketBeat Ratings reports. Five investment analysts have rated the stock with a buy rating. The average 1-year price target among analysts that have issued a report on the stock in the last year is $26.00. Market

[KayakerBC]

Be careful floating higher and higher.  The rarified air up there might just leave you gasping for breath and you will crash back down to earth.

[narmac]

,,wooow,,thats a tad disrespectful to say that about DrDR,,,Our CEO has made the comparison,,not me!!,,and you think contacting IR about their granting activity and the optics and perception by the market is pushing it.,,,,,,odd,,very odd,,,,,,I am just trying to figure out what point/s our CEO is actually been compared to BTI!!!,,,,Seems logical!

[KayakerBC]

narmac, you keep posting the Annexon comparison so explain it to me.  How are current shareholders -- at these stock prices -- going to survive the financing and dilution for the upcoming Phase II GBS trial, followed by the dilution in the move to the NASDAQ?  Lay out a scenario (with some numbers) for how it all unfolds.  How do we end up uncrushed when the dust from all that

[narmac]

"How are current shareholders -- at these stock prices -- going to survive the financing and dilution" How much dilutiuon will be required is an unknown,,,,,,I think up front $$$ is coming which would offset a major issue around such a move. And, also we could have a major move in stock price with some hard data. Either or, or other is yet to materialize. "the dilution in the move

[KayakerBC]

Ill say we go to $1 before financing occurs. That will require at least the start of a clinical trial IMO.  Or more likely imminent results from a trial to get to $1.  Count me doubtful.

[narmac]

,,,I am doubtful as well,,,,not sure how she will do it but I certainly think DrDR has some options in the wings to get what meets the objectives. And those options probably need the other side of the table to decide and move. Something she doesnt control. Just an opinion. I am shocked the speculators have not decended on this stock many months ago. It must be assumed they are waiting to see what

[prophetoffactz]

",,,I am doubtful as well,,,,not sure how she will do it but I certainly think DrDR has some options in the wings to get what meets the objectives. And those options probably need the other side of the table to decide and move. Something she doesnt control." BTI said the burn rate could consume the cash in about one month. Now we are about 50% past one month. They are waiting for some

[narmac]

Hummmm,,,,,Cresence also has an Alzheimer molecule called,,,,CRES203,,,,,,can we get our mitts on that one to is the question!!!

[prophetoffactz]

Looking for a 'Saltarelli' Saltarelli is with BTI by choice and he plays to win with scientific excellence on a global basis. A deal is a perfect place for a 'saltarelli' to surface and given there has been no financing announced and BTI was forecast to be out of money by now let's see a deal(s). Somewhere in here should be a 'saltarelli'.

[G1945V]

Zacks Small-Cap Valuation is US $0.70 !! G1945V

[G1945V]

For BTI that is !! Why the comparison with "ANNX" ?

[narmac]

Why the comparison with Annexon?,,,and our Zack target is 92 cents CAD. Good question,,, I have been looking thru some of the data from ANNX and they are certainly ahead of us based on what BTI has compiled around its xB3. However with the Cresense deal I cant decipher ruffly where we are now with these assets.  We are told we bought  ,,,"Phase 2 ready assets aligned with our

[narmac]

Annexon Biotech company   Annexon (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders of the